Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Molar mass | 147 kg/mol |
![]() ![]() |
Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug.[1] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] Development of the drug was ultimately discontinued with termination of all trials.[5]
| |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (initiation) |
| ||||||||||||||
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |